复星医药(02196.HK)向澳门供应首批10.5万剂新冠疫苗
复星医药(02196.HK)公布,2月23日,mRNA新冠疫苗BNT162b2获得中国澳门特别行政区卫生局特别许可进口批准、供中国澳门卫生局使用於当地新冠病毒疫苗接种计划,所涉疫苗数量不超过10.5万剂。
澳门政府已计划采购共计40万剂(包括本次特别进口许可数量在内)mRNA新冠疫苗BNT162b2用於当地新冠病毒疫苗接种计划,本次特别进口许可以外的其余部分,将根据澳门政府新冠病毒疫苗接种计划的实施需求等再次申请并进行审批。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.